CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

CSL makes $4bn+ move in mRNA vaccines with Arcturus deal

Source: 
Pharmaphorum
snippet: 

Australia’s CSL is the latest vaccines company to buy into the mRNA category, tapping US biotech Arcturus Therapeutics for a wide-ranging alliance targeting COVID-19, influenza and other respiratory pathogens, including those that may cause future pandemics.